BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2021 Results - Earnings Call Transcript

BioNTech SE shares (NASDAQ: BNTX) opened 8% up on Wednesday after the pharmaceutical company handily beat Street expectations for Q4 earnings and revenue. Notable figures in BioNTech Q4 earnings report Net profit printed at €3.17 billion ($3.51 billion), compared to last year's €3.66 million.

BioNTech reports unbelievable YoY growth for its fiscal Q4

BioNTech SE (NASDAQ: BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE: PFE) delivered approximately 2.6 billion.

Why BioNTech Shares Are Surging Today

German pharmaceutical company BioNTech SE reported soaring earnings and revenue for the fourth quarter, driven by the Covid-19 vaccine it produces with Pfizer Inc, and said it is starting a share buyback program of up to $1.5 billion over the next two years.

Dow Jones Newswires: BioNTech reports soaring earnings, revenue on COVID vaccine, plans $1.5 billion in buybacks

BioNTech says it plans to buy back up to $1.5 billion of stock over the next two years. It also will propose to pay a special dividend of €2 a share.

BioNTech's Earnings Top Estimates. It Plans a Buyback and Special Dividend.

Conference call and webcast scheduled for March 30, 2022 at 8:00 am ET (2:00 pm CET)

BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Moderna

The FDA expands its authorization for both companies' coronavirus vaccines.

Why Moderna and BioNTech Were Winners Today

Pfizer

The FDA has approved a second round of the Moderna Inc (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE), and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines for older people and certain immunocompromised individuals.  The agency said the new boosters would be.

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

Chewy

Lululemon Athletica

Micron Technology

Markets were off to a positive start on Tuesday, with the Nasdaq leading the charge with a gain of just over 1%.

Earnings Previews: BioNTech, Chewy, Lululemon, Micron

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine. The FDA also has authorized a second booster dose for individuals 12 years of age and older who have been determined to have certa

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

Walgreens

Chewy, Micron, Walgreens, Lululemon, and BioNTech release results this week. Plus, the March jobs report, February personal income and expenditures, and more economic data.

BioNTech, Chewy, Lululemon, Walgreens, and Other Stocks to Watch

Eli Lilly

Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.

Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal

Here's why America's largest pharmaceutical company splashed out on an experimental treatment you've probably never heard of.

How Pfizer's $6.7 Billion Arena Pharmaceuticals Buyout Could Work for Investors

Novavax

Investors appear to be concerned that Uncle Sam won't foot the bill for additional COVID-19 vaccine purchases.

Why Moderna, BioNTech, and Novavax Stocks Are Tumbling Today

Ocugen, Inc.

The picture is improving for vaccine stocks. But there's still a lot of uncertainty.

Is It Time to Buy COVID-19 Vaccine Stocks Again?

The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.

FDA Panel to Discuss Fourth Booster Dose in April Meeting

The momentum from earlier this week continues.

Why BioNTech Stock Is Jumping Today

BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $165, moving +0.66% from the previous trading session.

BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know

Pfizer Inc (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX) filed an application with the U.S. Food and Drug Administration this morning to approve emergency use authorization for a second booster shot of its Covid-19 vaccine.

Vaccine Stocks Rising on Booster News

Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.

Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults

MAINZ, GERMANY, March 16, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2021 on Wednesday, March 30th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2021.

BioNTech to Report Full Year and Fourth Quarter 2021 Financial Results and Operational Update on March 30, 2022

NEW YORK and MAINZ, GERMANY, March 15, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The submission is based on two real-world data sets from Israel analyzed at a time when the Omicron variant was widely circulating. Both data sets showed evidence that an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and severe illness.

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults

Johnson & Johnson

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

Vaccine maker stocks rise as China battles worst Covid outbreak since 2020

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Here's Why BioNTech Shares Are Rising On Monday

Dynavax Technologies

The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.

News for BioNTech SE Stock (BNTX)